Daiichi Sankyo Co., Ltd.’s European subsidiary will invest €1bn ($1.08bn) in an existing production and development site in Pfaffenhofen, Germany to expand its capabilities as an innovative center for cancer therapy, including R&D laboratories focusing on antibody-drug conjugate (ADC) technology and additional production capacity for cardiovascular drugs.
The expansion project has already started and is expected to create at least 350 new jobs, including researchers and engineers, by 2030